Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway

Biological and Pharmaceutical Bulletin

Volumn 38, Issue 2, 2015, Pages 277-284

  Wang, Zhendong ^a   Yang, Lei ^a   Xia, Yuanzheng ^a   Guo, Chao ^a   Kong, Lingyi ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Icariin; Multidrug resistance (MDR); Osteosarcoma; Phosphatidyl inositol 3 kinase (PI3K) Akt pathway

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DOXORUBICIN; ICARIIN; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RHODAMINE 123; VERAPAMIL;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CHINESE MEDICINE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RETENTION; DRUG SENSITIZATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; OSTEOSARCOMA CELL; OSTEOSARCOMA CELL LINE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84964203356     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00663     Document Type: Article

References (31)

1. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J. Clin. Oncol., 24, 3789-3798 (2006).
2. Mader RM, Schmidt WM, Steger GG, Krupitza G. Molecular mechanisms of drug resistance. Int. J. Clin. Pharmacol. Ther., 47, 49-50 (2009).
3. Wen J, Zheng B, Hu Y, Zhang X, Yang H, Luo KJ, Zhang X, Li YF, Fu JH. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line. Oncol. Rep., 22, 65-71 (2009).
4. Wei L, Song XR, Wang XW, Li M, Zuo WS. Expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcoma and their correlation with chemotherapy resistance. Zhonghua Zhong Liu Za Zhi, 28, 445-448 (2006).
5. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer, 5, 275-284 (2005).
6. Guns ES, Bullock PL, Reimer ML, Dixon R, Bally M, Mayer LD. Assessment of the involvement of CYP3A in vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes. Eur. J. Drug Metab. Pharmacokinet., 26, 273-282 (2001).
7. Kuppens IE, Witteveen EO, Jewell RC, Radema SA, Paul EM, Mangum SG, Beijnen JH, Voest EE, Schellens JH. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin. Cancer Res., 13, 3276-3285 (2007).
8. Morschhauser F, Zinzani PL, Burgess M, Sloots L, Bouafia F, Dumontet C. Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar·3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk. Lymphoma, 48, 708-715 (2007).
9. Müller H, Pajeva IK, Globisch C, Wiese M. Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg. Med. Chem., 16, 2448-2462 (2008).
10. Molnár J, Engi H, Hohmann J, Molnar P, Deli J, Wesolowska O, Michalak K, Wang Q. Reversal of multidrug resistance by natural substances from plants. Curr. Top. Med. Chem., 10, 1757-1768 (2010).
11. Palmeira A, Sousa E, Vasconcelos MH, Pinto MM. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr. Med. Chem., 19, 1946-2025 (2012).
12. Bansal T, Jaggi M, Khar RK, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J. Pharm. Pharm. Sci., 12, 46-78 (2009).
13. Zhang DW, Cheng Y, Wang NL, Zhang JC, Yang MS, Yao XS. Effects of total flavonoids and flavonol glycosides from Epimedium koreanum NAKAI on the proliferation and differentiation of primary osteoblasts. Phytomedicine, 15, 55-61 (2008).
14. Huang X, Zhu DY, Lou Y. A novel anticancer agent, icaritin, induced cell growth inhibition, G(1) arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. Eur. J. Pharmacol., 564, 26-36 (2007).
15. Ning HX, Xin ZC, Lin GT, Banie L, Lue TF, Lin CS. Effects of icariin on phosphodiesterase-5 activity in vitro and cyclic guanosine monophosphate level in cavernous smooth muscle cells. Urology, 68, 1350-1354 (2006).
16. Oda Y, Matsumoto Y, Harimaya K, Iwamoto Y, Tsuneyoshi M. Establishment of new multidrug-resistant human osteosarcoma cell lines. Oncol. Rep., 7, 859-866 (2000).
17. Roncuzzi L, Pancotti F, Baldini N. Involvement of HIF-1alpha activation in the doxorubicin resistance of human osteosarcoma cells. Oncol. Rep., 32, 389-394 (2014).
18. Judson PL, Geller MA, Bliss RL, Boente MP, Downs LS Jr, Argenta PA, Carson LF. Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer. Gynecol. Oncol., 91, 389-394 (2003).
19. Si M, Zhao J, Li X, Tian JG, Li YG, Li JM. Reversion effects of curcumin on multidrug resistance of MNNG/HOS human osteosarcoma cells in vitro and in vivo through regulation of P-glycoprotein. Chin. Med. J., 126, 4116-4123 (2013).
20. Wang J, Yin JQ, Jia Q, Shen JN, Huang G, Xie XB, Zou CY. Bufalin induces apoptosis in osteosarcoma U-2OS and U-2OS methotrexate 300-resistant cell lines in vitro. Zhonghua Zhong Liu Za Zhi, 32, 734-738 (2010).
21. Díaz-Montero CM, McIntyre BW. Acquisition of anoikis resistance in human osteosarcoma cells does not alter sensitivity to chemotherapeutic agents. BMC Cancer, 5, 39 (2005).
22. Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, Montrose MH, Beck WT, Erickson LC. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J. Pharmacol. Exp. Ther., 324, 95-102 (2008).
23. Jiang H, Fan D, Zhou G, Li X, Deng H. Phosphatidylinositol 3-kinase inhibitor (LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo. J. Exp. Clin. Cancer Res., 29, 34 (2010).
24. Deback C, Geli J, Ait-Arkoub Z, Angleraud F, Gautheret-Dejean A, Agut H, Boutolleau D. Use of the Roche LightCycler (R) 480 system in a routine laboratory setting for molecular diagnosis of opportunistic viral infections: Evaluation on whole blood specimens and proficiency panels. J. Virol. Methods, 159, 291-294 (2009).
25. Broxterman HJ, Giaccone G, Lankelma J. Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Curr. Opin. Oncol., 7, 532-540 (1995).
26. Gottesman MM. Cancer gene therapy: an awkward adolescence. Cancer Gene Ther., 10, 501-508 (2003).
27. Diestra JE, Condom E, Del Muro XG, Scheffer GL, Perez J, Zurita AJ, Munoz-Segui J, Vigues F, Scheper RJ, Capella G, Germa-Lluch JR, Izquierdo MA. Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: Biological and clinical implications. J. Urol., 170, 1383-1387 (2003).
28. Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr. Relat. Cancer, 10, 43-73 (2003).
29. Coffey JC, Wang JH, Smith MJF, Laing A, Bouchier-Hayes D, Cotter TG, Redmond HP. Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. J. Biol. Chem., 280, 20968-20977 (2005).
30. Luan Y, Yang Q, Xie Y, Duan S, Cai S, Forrest ML. A sensitive near-infrared fluorescent probe for caspase-mediated apoptosis: Synthesis and application in cell imaging. Drug Discov. Ther., 5, 220-226 (2011).
31. Zhang Y, Johansson E, Miller ML, Janicke RU, Ferguson DJ, Plas D, Meller J, Anderson MW. Identification of a conserved anti-apoptotic protein that modulates the mitochondrial apoptosis pathway. PLoS ONE, 6, e25284 (2011).